Literature DB >> 19299498

Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.

Helen E Davies1, Ross S Sadler, Silvia Bielsa, Nicholas A Maskell, Najib M Rahman, Robert J O Davies, Berne L Ferry, Y C Gary Lee.   

Abstract

RATIONALE: Serum mesothelin is a new biomarker for the diagnosis of mesothelioma. Patients with mesothelioma commonly present with pleural effusions. To define the clinical utility of mesothelin quantification in pleural fluid, we assessed its additional value over pleural fluid cytology and its short-term reproducibility and reliability after pleural inflammatory processes, including pleurodesis.
OBJECTIVES: To assess the diagnostic role of pleural fluid mesothelin and the effect of common clinical factors that may influence measurement accuracy.
METHODS: Mesothelin was quantified in 424 pleural fluid and 64 serum samples by ELISA. Fluid was collected prospectively from 167 patients who presented with pleural effusions for investigation. Serial pleural fluid samples were obtained from patients (n = 33) requiring repeated drainage. Mesothelin levels were also measured in patients (n = 32) prepleurodesis and postpleurodesis.
MEASUREMENTS AND MAIN RESULTS: Pleural fluid mesothelin concentrations were significantly higher in patients with mesothelioma (n = 24) relative to those with metastatic carcinomas (n = 67) and benign effusions (n = 75): median (interquartile range, 25th-75th percentile) = 40.3 (18.3-68.1) versus 6.1 (1.5-13.2) versus 3.7 (0.0-12.4) nM, respectively, P < 0.0001. Mesothelin measurement was superior to cytological examination in the diagnosis and exclusion of mesothelioma (sensitivity, 71 vs. 35%; specificity, 89 vs. 100%; negative predictive value, 95 vs. 82%, respectively). In patients with "suspicious" cytology, pleural fluid mesothelin was 100% specific for mesothelioma, and in cytology-negative effusions (n = 105) offered a negative predictive value of 94%. Intraindividual reproducibility of pleural fluid mesothelin was excellent: mean (+/-SD) variation, -0.15 (+/-8.41) nM in samples collected within 7 days from patients with mesothelioma. Measurements remained reliable after pleurodesis and were not affected by the presence of bacteria.
CONCLUSIONS: Pleural fluid mesothelin provides additional diagnostic value relative to cytological examination. Mesothelin measurements are reproducible and not affected by inflammatory pleural processes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19299498     DOI: 10.1164/rccm.200811-1729OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  29 in total

Review 1.  What's the place of immunotherapy in malignant mesothelioma treatments?

Authors:  Marc Grégoire
Journal:  Cell Adh Migr       Date:  2010-01-30       Impact factor: 3.405

2.  The continual search for ideal biomarkers for mesothelioma: the hurdles.

Authors:  Fraser J Brims; Y C Gary Lee; Jenette Creaney
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

3.  Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.

Authors:  Mehmet Bayram; Isa Dongel; Ali Akbaş; Ismail Benli; Muhammed Emin Akkoyunlu; Nur Dilek Bakan
Journal:  Lung       Date:  2013-10-30       Impact factor: 2.584

4.  fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.

Authors:  Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Expert Opin Med Diagn       Date:  2011-05-01

5.  Individual predictors of increased serum mesothelin in asbestos-exposed workers.

Authors:  Rosa Filiberti; Paola Marroni; Manlio Mencoboni; Virginia Mortara; Pietro Caruso; Alex Cioè; Luigi Michelazzi; Domenico F Merlo; Andrea Bruzzone; Barbara Bobbio; Lisette Del Corso; Roberto Galli; Paola Taveggia; Guglielmo Dini; Fabio Spigno
Journal:  Med Oncol       Date:  2013-01-01       Impact factor: 3.064

Review 6.  Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy.

Authors:  Seiki Hasegawa; Nobuyuki Kondo; Seiji Matsumoto; Teruhisa Takuwa; Masaki Hashimoto; Hayato Orui; Shunichi Fukuda; Kazue Yoneda; Yoshitomo Okumura; Noriaki Tsubota; Kazuya Fukuoka; Ikuko Torii; Tohru Tsujimura; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2012-01-12       Impact factor: 3.402

7.  Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.

Authors:  Jingli Zhang; Shuo Qiu; Yujian Zhang; Maria Merino; Patricia Fetsch; Itzhak Avital; Armando Filie; Ira Pastan; Raffit Hassan
Journal:  Anticancer Res       Date:  2012-12       Impact factor: 2.480

8.  Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.

Authors:  Rosa Filiberti; Stefano Parodi; Roberta Libener; Giovanni Paolo Ivaldi; Pier Aldo Canessa; Donatella Ugolini; Barbara Bobbio; Paola Marroni
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

Review 9.  Management of malignant pleural effusion.

Authors:  Jack A Kastelik
Journal:  Lung       Date:  2013-01-13       Impact factor: 2.584

10.  Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report.

Authors:  Pier Aldo Canessa; Paola Ferro; Carmen Manta; Massimiliano Sivori; Maria Cristiana Franceschini; Franco Fedeli; Silvio Roncella
Journal:  Med Oncol       Date:  2013-07-20       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.